Hana Pharm held a groundbreaking ceremony on July 2020 to celebrate the start of the new facility
Hana Pharm held a groundbreaking ceremony on July 2020 to celebrate the start of the new facility
# Marks the start of securing a full-fledged growth momentum
# Investment of $48.8 million (KRW 58.5 billion), increasing the production capacity by 15 million vials and 15 million ampoules per year
# Aims to supply injectables such as remimazolam to the global market through meeting EU GMP compliance
Hana Pharm (KOSPI 293480, CEO Younha Lee) held a groundbreaking ceremony on July 29th for the new facility at the existing Hagil Plant located in the industrial complex in Balan, Hwaseong-si. The establishment is scheduled to be completed by October 2021, and will have an exclusive production line for their specialized injectables. The expected maximum capacity will be 15 million vials for lyophilized and 15 million ampoules for plastics per year, and is definitely expected to play a key role in Hana Pharm’s growth momentum.
The new facility consists of 4 floors - 3 floors and 1 basement level located at the existing site, with a total area of 10,726.88㎡. Major production lines include lyophilized injection line for their NCE product, Remimazolam, and BFS (Blow Fill Seal) line for plastic ampoules. Through this new facility after earning a certificate of EU GMP compliance, Hana Pharm plans to supply high quality products to the global market.
<Photo: Hana Pharm, Ee-hwa Construction (Constructor) officials ? New facility groundbreaking ceremony>
Dr. Younha Lee, CEO of Hana Pharm, stated, “The new facility has a significant meaning as a starting point for securing our growth momentum.” He also added, “Remimazolam received the approval both in Japan and in the US already, and is strongly expected to be approved in various regions including EU and South Korea this year. To fulfill the unmet need for potential anesthetic market worldwide, we will expand the production capacity and also proceed to export our highly qualified products including remimazolam abroad."
